161 related articles for article (PubMed ID: 38595196)
1. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses.
Baik SH; Baye F; McDonald CJ
Menopause; 2024 May; 31(5):363-371. PubMed ID: 38595196
[TBL] [Abstract][Full Text] [Related]
2. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
3. Transdermal hormone therapy and the risk of stroke and venous thrombosis.
Speroff L
Climacteric; 2010 Oct; 13(5):429-32. PubMed ID: 20670199
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and progestogen effect on venous thromboembolism in menopausal women.
Archer DF; Oger E
Climacteric; 2012 Jun; 15(3):235-40. PubMed ID: 22612609
[TBL] [Abstract][Full Text] [Related]
5. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
6. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.
Harman SM; Vittinghoff E; Brinton EA; Budoff MJ; Cedars MI; Lobo RA; Merriam GR; Miller VM; Naftolin F; Pal L; Santoro N; Taylor HS; Black DM
Am J Med; 2011 Mar; 124(3):199-205. PubMed ID: 21396500
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
[TBL] [Abstract][Full Text] [Related]
8. Different menopausal hormone regimens and risk of breast cancer.
Brusselaers N; Tamimi RM; Konings P; Rosner B; Adami HO; Lagergren J
Ann Oncol; 2018 Aug; 29(8):1771-1776. PubMed ID: 29917061
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
10. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.
Shufelt CL; Merz CN; Prentice RL; Pettinger MB; Rossouw JE; Aroda VR; Kaunitz AM; Lakshminarayan K; Martin LW; Phillips LS; Manson JE
Menopause; 2014 Mar; 21(3):260-6. PubMed ID: 24045672
[TBL] [Abstract][Full Text] [Related]
11. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
[TBL] [Abstract][Full Text] [Related]
12. Is the WHI relevant to HRT started in the perimenopause?
Harman SM; Brinton EA; Clarkson T; Heward CB; Hecht HS; Karas RH; Judelson DR; Naftolin F
Endocrine; 2004 Aug; 24(3):195-202. PubMed ID: 15542885
[TBL] [Abstract][Full Text] [Related]
13. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.
Tang JY; Spaunhurst KM; Chlebowski RT; Wactawski-Wende J; Keiser E; Thomas F; Anderson ML; Zeitouni NC; Larson JC; Stefanick ML
J Natl Cancer Inst; 2011 Oct; 103(19):1469-75. PubMed ID: 21878677
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk in relation to the interval between menopause and starting hormone therapy.
Beral V; Reeves G; Bull D; Green J;
J Natl Cancer Inst; 2011 Feb; 103(4):296-305. PubMed ID: 21278356
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.
Chlebowski RT; Anderson GL; Aragaki AK; Prentice R
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26546117
[TBL] [Abstract][Full Text] [Related]
17. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
[TBL] [Abstract][Full Text] [Related]
18. Changing concepts: Menopausal hormone therapy and breast cancer.
Chlebowski RT; Anderson GL
J Natl Cancer Inst; 2012 Apr; 104(7):517-27. PubMed ID: 22427684
[TBL] [Abstract][Full Text] [Related]
19. Long-term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J; Farquhar C; Roberts H; Lethaby A; Lee J
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004143. PubMed ID: 28093732
[TBL] [Abstract][Full Text] [Related]
20. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
